Hyderabad: Biological E Ltd, a Hyderabad-based vaccine company, on Monday said it has bagged a ₹ 895 crore order from the ministry of health and family welfare to supply ComBE Five—the 5-in-1 liquid pentavalent vaccine (LPV)—for the universal immunisation programme.
Biological E will supply ComBE Five for a period of two years, the company said in a statement.
ComBE Five vaccine protects children from diphtheria, pertussis (whooping cough), tetanus, hepatitis B and Haemophilus influenzae type B (Hib) which causes pneumonia and meningitis.
Pentavalent vaccine is less traumatic for babies to receive and easier to administer and store.
The vaccine will be inducted into the government’s universal immunisation programme as part of Mission Indradhanush, to immunise all children against seven vaccine-preventable diseases—namely, diphtheria, whooping cough (pertussis), tetanus, polio, tuberculosis, measles and hepatitis B by 2020.
This vaccine is expected to make a significant contribution to reducing ‘under five years mortality’ rates in India, the company said.
Biological E’s ComBE Five has received the World Health Organization’s pre-qualification approval in 2012 and has been exported to several countries.
So far the company has supplied more than 200 million doses of pentavalent vaccine for various national and global immunisation programmes across the world.
As part of its expansion plan, Biological E said it is investing more than ₹ 500 crore on building new facilities over a period of three years to augment its production capacity for vaccines as well as complex generics.